Dr. Gilbert Tang/X
Nov 13, 2025, 01:15
Dr. Gilbert Tang Shares NEJM Late-Breaker: 7-Year Outcomes Reinforce TAVR as a Durable Option for Low-Risk Aortic Stenosis
Dr. Gilbert Tang, Vice Chair of Innovation, Cardiovascular Surgery Surgical and Academic Director at Mount Sinai Health System, shared a post on X:
“TCT2025 Late breaker PARTNER 3 Low Risk 7 Year Sapien3 TAVR vs SAVR showed no significant differences in composite endpoint, all-cause mortality, CV mortality, and low reintervention rates in both arms. Clinical valve thrombosis 2.8% TAVR vs 0.5% SAVR but similar BVF (valve failure) and reintervention.
Paper now online The New England Journal of Medicine (NEJM)
and can download here.

Nice TCTMD article.”
Stay updated with Hemostasis Today.
-
Dec 15, 2025, 15:58Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
-
Dec 15, 2025, 12:46Deborah Ebert Long on Hemophilia Care: Progress, Possibility, and the Power of Listening
-
Dec 15, 2025, 12:34Nathan Connell on Conversion from Eptacog Alfa to Beta
-
Dec 15, 2025, 12:17Danny Hsu on Interdisciplinary Toolkit for Gynecologic Bleeding on Anticoagulation
-
Dec 15, 2025, 12:08Ted Roh: A Historic Milestone for Indonesia’s Health Innovation
-
Dec 15, 2025, 11:28Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
-
Dec 15, 2025, 11:12Tushar Pandey Awarded for His Enourmous Contribution to Hematology
-
Dec 15, 2025, 11:07DISTRO: Vidya Rajbhoj on AI and Digital Technology to Improve Stroke Rehabilitation
-
Dec 15, 2025, 11:00Ischemic Stroke, AF and Atherosclerotis: Amira Khater on Sufficiency of Anticoagulant Monotherapy
